MTOR and breast carcinoma: Furthermore, existing research indicated compound 17 suppressed tumur stemness, proliferation, migration, and epithelial-mesenchymal transition (EMT) in breast cancer by inhibiting the PI3K/Akt/mTOR pathway and stemness-related genes, such as SRY-box2 and Nanog38.